Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01261247 · ClinicalTrials.gov registry record · Phase 2

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
41
Enrollment target
2
Study locations

NCT01261247: Completed Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Mayo Clinic.

NCT01261247 is a Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma that has completed, run by Mayo Clinic. The registered enrollment target is 41 participants, below the 105-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01261247, a Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
41 participants
Enrollment target
2
Study locations

Study Summary

Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma

Primary Outcome

The primary endpoint of this phase II trial is the proportion of confirmed responses (complete response (CR) or partial response (PR)) noted as the objective status and will be considered synonymous with "success" for this study.Response will be evaluated using all cycles of treatment. A CR is defined using the Cheson et al. Revised Response Criteria for Malignant Lymphoma as Disappearance of all evidence of disease. A PR is defined as Regression of measurable disease and no new sites with ≥50%

Conditions Studied

Peripheral T-Cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Adult Nasal Type Extranodal NK/T-cell Lymphoma Hepatosplenic T-cell Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Burkitt Lymphoma Post-transplant Lymphoproliferative Disorder

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG panobinostat
  • OTHER flow cytometry
  • GENETIC DNA analysis
  • GENETIC western blotting

Study Locations (2)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2011-01-17
Est. Completion 2019-12-02
Phase Phase 2
Mayo Clinic

2,844 total trials

What the finished NCT01261247 record still lists

NCT01261247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 105-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (61% lower).

The record links to 10 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT01261247 reports a single indexed study location in Arizona, Minnesota.

Frequently Asked Questions

What is clinical trial NCT01261247 about?

NCT01261247 is a clinical study titled "Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma". Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma

What is the current status of trial NCT01261247?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2011-01-17. Estimated completion is 2019-12-02.

What conditions does trial NCT01261247 study?

This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma.

What interventions are being tested in trial NCT01261247?

The interventions under investigation include: laboratory biomarker analysis (OTHER), panobinostat (DRUG), flow cytometry (OTHER), DNA analysis (GENETIC), western blotting (GENETIC).

Who is sponsoring clinical trial NCT01261247?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01261247 being conducted?

This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Peripheral T-Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01261247's enrollment target sits among peer trials

41 19th of 34 higher than 16 of 34 other Peripheral T-Cell Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01261247, the US trial registry maintained by the National Library of Medicine. NCT01261247 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.